Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Roche’s patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.
Homicide investigators have taken over the investigation into the weekend death of Apotex Chairman of the Board and founder Barry Sherman and his wife, Honey.
Industry analysts were shocked when in July the FDA reversed course on Amicus’ Phase III treatment for Fabry disease.
The Mass. Attorney General said the deal will resolve an investigation by her office and those in four other states related to Medtronic’s promotion of Infuse.
The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.
Craig Dees, CEO of Provectus treated the company as “his own personal piggy bank” by submitting hundreds of falsified records to obtain $3.2M for personal expenses
The company’s vaccine controversy could cause legal and image problems for years to come.
Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.
One of the biggest concerns has been the loss of the R&D tax credit, which incentivizes companies, including life science firms, to support research.
In the wake of sexual harassment allegations, OrbiMed Advisors’ founder and managing partner Sam Isaly has stepped down from his position.